

# Contents

Preface.....	xiii
Acknowledgments.....	xv
Abbreviations.....	xvii
SECTION I. History and Background.....	1
Chapter 1. History and Background of Clinical Trials.....	3
SECTION II. Protocol Development.....	11
Chapter 2. Assurances.....	13
Chapter 3. Elements of a Protocol.....	17
Chapter 4. Workload Determination and Resource Allocation.....	21
Chapter 5. Budget.....	31
Chapter 6. Statistical Considerations in Protocol Development.....	41
SECTION III. Preparation and Assessment.....	49
Chapter 7. Safety Issues.....	51
Chapter 8. Sponsoring Agencies: Industry.....	55
Chapter 9. Potential Accrual Base.....	59
Chapter 10. Educating Staff.....	63
Chapter 11. Clinical Research/Interdisciplinary Team.....	69
SECTION IV. Legislative and Regulatory Issues.....	77
Chapter 12. Introduction to Legal and Regulatory Issues.....	79
Chapter 13. Institutional Review Boards/Protocol Modifications.....	91
Chapter 14. Informed Consent.....	97
Chapter 15. Compassionate Use of Investigational Drugs.....	107
Chapter 16. Conflicts of Interest.....	111
Chapter 17. Legislative Issues.....	115
Chapter 18. General Publication and Authorship Policies for Nurses.....	123
SECTION V. Promotion and Patient Retention.....	131
Chapter 19. Psychosocial Considerations.....	133
Chapter 20. Public and Patient Education.....	141
Chapter 21. Recruitment and Promotion Strategies for Clinical Trials.....	147
Chapter 22. Eligibility.....	151
Chapter 23. Designing a Computerized Tool to Verify Eligibility.....	155
Chapter 24. Prevention and Control Study Considerations.....	167
SECTION VI. Active Treatment.....	177
Chapter 25. Investigational Agents and Procurement of Research Study Drugs.....	179
Chapter 26. Administration of Protocol Agents.....	189
Chapter 27. Symptom Management in Clinical Trials Nursing.....	193
Chapter 28. Adverse Events.....	197
Chapter 29. Patient and Family Education.....	215
Chapter 30. Adherence in Clinical Trials.....	223
SECTION VII. Ancillary Studies.....	229
Chapter 31. Quality-of-Life Studies.....	231
Chapter 32. Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics.....	235
Chapter 33. Genetic Testing and Storage of Genetic Material.....	243

CONTENTS

Chapter 34. Pharmacoeconomic Studies .....	249
Chapter 35. Nursing Companion Studies .....	253
SECTION VIII. Off-Treatment Follow-Up .....	257
Chapter 36. Off-Treatment Protocol Considerations .....	259
Chapter 37. Long-Term Follow-Up .....	263
Chapter 38. Off-Treatment Documentation .....	267
SECTION IX. Data Management and Reporting .....	271
Chapter 39. The Need for Data Management Tools .....	273
Chapter 40. Documentation and Forms Submissions .....	287
Chapter 41. Electronic Data Capture in Clinical Trials .....	289
Chapter 42. Clinical Data Management Systems .....	293
Chapter 43. Cancer Trials Support Unit: A Service of the National Cancer Institute .....	301
Chapter 44. Clinical Trial Registries .....	305
SECTION X. Quality Management .....	313
Chapter 45. Good Clinical Practice .....	315
Chapter 46. Standard Operating Procedures .....	323
Chapter 47. Audit Preparation .....	329
Chapter 48. Community-Based Clinical Trials .....	335
Chapter 49. Drug Accountability .....	339
Chapter 50. Interdisciplinary Team Review .....	345
SECTION XI. Professional Development .....	351
Chapter 51. Specialization in Clinical Trials Nursing .....	353
Chapter 52. Mentorship .....	357
Chapter 53. Professional Continuing Education .....	363
SECTION XII. International Considerations .....	367
Chapter 54. Australia .....	369
Chapter 55. New Zealand .....	377
Chapter 56. Canada .....	383
Chapter 57. Japan .....	391
Chapter 58. European Union Directives .....	403
Chapter 59. Austria .....	409
Chapter 60. Denmark .....	413
Chapter 61. France .....	417
Chapter 62. Germany .....	421
Chapter 63. Italy .....	429
Chapter 64. United Kingdom .....	439
Appendices .....	451
Appendix 1. Nuremberg Code .....	453
Appendix 2. Declaration of Helsinki .....	454
Appendix 3. National Research Act, Public Law 93-348, July 12, 1974 .....	456
Appendix 4. The Belmont Report .....	457
Appendix 5. Code of Federal Regulations .....	463
Appendix 6. International Conference on Harmonisation Guideline for Good Clinical Practice .....	476
Appendix 7. Federalwide Assurance Terms .....	501
Appendix 8. Federalwide Assurance Template .....	507
Appendix 9. Individual Investigator Agreement .....	509
Appendix 10. Informed Consent Document Template .....	510
Appendix 11. National Cancer Institute Return Agent Form .....	520
Appendix 12. National Cancer Institute Transfer Investigational Agent Form .....	521
Appendix 13. Internet Resource List .....	522
Index .....	525